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Abstract: Malaria is a life-threatening disease and, what is more, the resistance to available antimalarial
drugs is a recurring problem. The resistance of Plasmodium falciparum malaria parasites to previous
generations of medicines has undermined malaria control efforts and reversed gains in child
survival. This paper describes a continuation of our ongoing efforts to investigate the effects against
Plasmodium falciparum strains and human microvascular endothelial cells (HMEC-1) of a series of
methoxy p-benzyl-substituted thiazinoquinones designed starting from a pointed antimalarial lead
candidate. The data obtained from the newly tested compounds expanded the structure–activity
relationships (SARs) of the thiazinoquinone scaffold, indicating that antiplasmodial activity is not
affected by the inductive effect but rather by the resonance effect of the introduced group at the
para position of the benzyl substituent. Indeed, the current survey was based on the evaluation of
antiparasitic usefulness as well as the selectivity on mammalian cells of the tested p-benzyl-substituted
thiazinoquinones, upgrading the knowledge about the active thiazinoquinone scaffold.
Keywords: thiazinoquinones; Plasmodium falciparum; quinone-derived antimalarial agents; marine
inspired compounds; cytotoxicity; antiparasitic agents
1. Introduction
The World Health Organization (WHO) considers human malaria as one of the major public health
burdens, affecting primarily populations in tropical and subtropical countries [1,2]. Pregnant women
and children are particularly vulnerable, but malaria infection is also a severe problem for travelers
who come into endemic regions and for immunocompromised people. The decrease in the number of
infected people, around 20 million fewer than 2010, is clear evidence of the great efforts made to fight
this parasite. Nevertheless, in the timeframe 2015–2017, no significant progress has been recorded in
term of a reduction of global malaria cases, with a remarkable percentage, approximatively 40%, of the
world’s population still at risk of infection [2]. An additional setback is represented by multiparasitism;
often, the malaria patient is co-infested by other parasite species, such as Schistosoma and Leishmania,
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classified as neglected tropical diseases (NTDs) due to the absence of efficient and consistent politics
based on prevention and a consequent lack of investments by pharmaceutical industries [3].
In the frame of our studies aiming to explore new chemical entities that can be employed for
the discovery of new drugs against malaria and other parasitic diseases [4–9], we have recently
identified the bicyclic 1,1-dioxo-1,4-thiazine system fused to the quinone ring as a new scaffold active
against P. falciparum and Schistosoma mansoni [4–9] exploiting natural marine metabolites as model
compounds [10–14]. This work, based on the model of natural marine metabolites, aplidinone A and B
(1 and 2), has yielded a chemical library of synthetic thiazinoquinones (3–22, Figure 1), which was
funneled into a large screening for the search of antimalarial agents [4,6,9]. Many of these compounds
have been demonstrated as effective antimalarials, but the research program has been focused on the
methoxy-substituted compounds (6–12 and 16–22, Figure 1). Structure–activity relationship (SAR)
studies evidenced that in this group of thiazinoquinones, only the compounds in which the methoxy
substituent on the quinone ring is on the same side of the nitrogen of the thiazine ring (regioisomers B)
were active, indicating this regiochemistry of the bicyclic moiety is a crucial requirement for the
antiplasmodial activity [4,6]. Thus, the synthetic protocol designed for the production of methoxy
thiazinoquinones with different alkyl side chains has been improved to make it as selective as possible
in favor of the active regioisomer [4,6]. Among the tested thiazinoquinones, we have identified
a lead candidate, compound 22, featuring a benzyl alkyl chain; it was found to be active in the
range of low-micromolar concentrations against both chloroquine-sensitive (D10) and -resistant (W2)
P. falciparum strains, and exhibited a good selectivity index (SI) on the tested mammalian cells (>25).
The key role of the thiazinoquinone heterocyclic moiety for the antiplasmodial activity was confirmed
by the absence of activity showed by compound 23, the corresponding quinone of 22 lacking the
thiazine ring (Figure 1) [6]. The proposed antimalarial mechanism of action for 22 has been related to
its capability to form a stable radical on the benzyl substituent that impairs the Plasmodium defense in
the heme group detoxification pathway [6]. Definitively, overall, these results supported the eligibility
of the thiazinoquinone as a new redox active scaffold, as an alternative to naphthoquinones [15], to be
explored for its properties as a lead for the development of novel antimalarials.
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Several antimalarial agents (e.g., artemisinin and its derivatives, chloroquine, mefloquine) are also
effective against other parasites [16–18]. This prompted us to investigate the effects against S. mansoni
of benzyl methoxy thiazinoquinone 22, of the quinone 23, and of the ad hoc synthesized p-substituted
benzyl derivatives of 22, compounds 24–27 (Figure 2). This study was performed in the frame of a
wider screening aiming to explore the potential of the methoxy thiazinoquinone system to search for
novel multi-stage antischistosomal agents [8,9]. In particular, the influence on the anti-parasitic activity
against P. falciparum D10 and W2 strains as well as mammalian cells of various electron-withdrawing
and -donating groups (-Cl, -CF3, -OCH3, and -OCF3) at the para position of the benzyl side chain
was evaluated.
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Thiazinoquinones 24–27, as well as the quinone 23, were first tested on schistosomula, the parasite
larval stage; then, their effects on the viability of adult worm pairs and juvenile parasites, as well as
on egg production and development, were evaluated. Interestingly, similar to what happens for the
antiplasmodial effect, compounds 23 and all the regioisomeric A forms of methoxy thiazinoquinones
were inactive [8]. All regioisomers B of p-substituted benzyl methoxy thiazinoquinones (compounds
24–27) were active on both parasite forms and eggs, with compounds 26 and 27 being the most potent
compounds in the series. In the present communication, a brief upgrade on the pharmacological effects
of compounds 24–27 is reported. Herein, we describe the not yet reported antiplasmodial behavior of
compounds 24–27 on D10 and W2 P. falciparum strains in vitro and their cytotoxicity against human
microvascular endothelial cells (HMEC-1). These results, integrated with those previously reported
on the schistosomicidal activity of these compounds, highlight compound 26 as a potential hit active
against both P. falciparum and S. mansoni.
2. Results and Discussions
Thiazinoquinones 24–27 (Figure 2) were prepared from the commercially available 1,2,4-
trimethoxybenzene as previously described [6,8]. In these compounds, the lead candidate 22 was
modified by introducing various substituents (both electron-withdrawing and -donating groups) in the
para position of the benzyl side chain. This chemical manipulation aimed to evaluate the possible effects
on the antiparasitic activity and thus provide further evidence on the mode of action of thiazinoquinone
derivatives. In our previously reported screening against S. mansoni, compounds 26 and 27, both
bearing an oxygen atom directly linked to the benzyl side chain, showed a better overall activity profile
against the different forms of the parasite (larval, adult and juvenile forms, eggs) when compared to
22 [8]. The higher activity of these two derivatives has been supposed to be related to the presence of
the H-bonds acceptor groups in the para position rather than the electronic effects on the aromatic ring
of the substituents. Indeed, it has been supposed that these groups could possibly play a crucial role in
the active thiazinoquinones, hypothesizing their membrane-transport proteins’ exploitation to enter
the parasite [8]. Likewise, the schistosomicidal drug of choice praziquantel (PZQ) has been proposed
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to compete with adenosine for its transport into the parasite by binding to the nucleoside transporter,
and SARs performed on PZQ indicated that its substitution with an aromatic moiety is detrimental,
unless it is a phenyl ring substituted in para by a H-bond donor/acceptor group [8,19].
In order to evaluate the influence on the antimalarial activity of the substituents placed on the
aromatic side chain of the lead candidate 22, compounds 24–27 were tested against chloroquine
(CQ)-sensitive (D10) and -resistant (W2) strains of P. falciparum by using the parasite lactate
dehydrogenase (pLDH) assay [20]. All the p-substituted benzyl derivatives of 22 retained activity
and were effective as antiplasmodial in the micromolar range. Moreover, compounds 24–27 were
evaluated for their cytotoxic effects against HMEC-1 cells, too. The IC50 values on both P. falciparum
strains and HMEC-1 cell line obtained for compounds 24–27, as well as those of the lead compound 22,
are reported in Table 1. For each compound, the selectivity index (SI), namely the ratio between the
IC50 values on the human cells and that on the parasite strains, was calculated; these data are reported
in Table 1, alongside those calculated considering the IC50 values previously reported for compounds
22 and 24–27 on embryonic murine fibroblasts (NIH-3T3 cell line) [8]. It can be observed that, for the
antiplasmodial activity, the IC50 values of compounds 24–27 are not significantly different from that
of the lead candidate 22 and, actually, the activity of all thiazinoquinones was slightly decreased.
The most remarkable lowering of the antiplasmodial activity was observed for compound 25, which
featured a substituent (-CF3) with a strong electron-withdrawing inductive effect at the para position
of the aromatic ring and no resonance effect. On the other hand, the groups introduced at the para
position of the benzyl ring of compounds 24, 26, and 27 (Figure 2), which showed lower IC50 values
than 25 (Table 1), although characterized in some cases by opposite inductive effects, share the presence
of a lone pair, which can be conjugated to the aromatic ring. Noteworthy, the potency of compound 27
was higher against the chloroquine-resistant W2 strain than against the D10 strain (see Table 1), with
an IC50 in the sub-micromolar concentration range (IC50 = 0.81 µM).
Table 1. IC50 in vitro values of compound 22 and 24–27 on chloroquine (CQ) a sensible (D10) b and
resistant (W2) b strains of P. falciparum; cytotoxicity on HMEC-1 cell line c and relevant selectivity index
(SI) d; SI on NIH-3T3 cell line e.
Compounds D10 IC50
(µM)
W2 IC50
(µM)
HMEC-1 IC50
(µM) c
SI d SI e
D10 W2 D10 W2
22 0.60 ± 0.21 0.70 ± 0.22 17.6 ± 1.4 29.3 25.2 147.7 126.5
24 1.63 ± 0.35 1.90 ± 1.05 8.51 ± 0.76 5.2 4.5 48.5 41.6
25 5.06 ± 1.68 5.02 ± 1.81 20.4 ± 1.60 4.0 4.1 11.0 11.1
26 1.21 ± 0.20 1.22 ± 0.24 17.9 ± 1.10 14.8 14.7 – f – f
27 1.12 ± 0.40 0.81 ± 0.19 3.59 ± 0.72 3.2 4.4 32.6 45.0
a CQ as positive control: D10 IC50 (µM) = 0.04 ± 0.01; W2 IC50 (µM) = 0.54 ± 0.28; not cytotoxic. b Data are the mean
± SD of three different experiments in duplicate. c Camptothecin as positive control: IC50 (µM) = 0.018 ± 0.008.
d SI = IC50 HMEC-1/IC50 P. falciparum strain. e SI = IC50 NIH-3T3/IC50 P. falciparum strain; cytotoxicity values on
NIH-3T3 (µM) of compounds 22 and 24–27 are reported in a previous work [8]. f SI was not calculated since 26 is
not active on NIH-3T3.
Definitively, as for the antiplasmodial activity, modification of the lead compound 22 did
not provide a better candidate. However, this study demonstrated that p-OCH3 and p-OCF3 benzyl
derivatives of 22, compounds 26 and 27, which have been highlighted as new promising schistosomicidal
multi-stage hits, both possess good antiplasmodial activity in the micromolar range, with compound
27 being more active among the two on the CQ-resistant strain W2.
As for the toxic effects exerted by compounds 26 and 27 on the cell growth of HMEC-1 (Table 1),
compound 27 (cLogD = 1.37) [8] was the most cytotoxic thiazinoquinone in the tested series with an IC50
value of 3.59 µM. On the contrary, the thiazinoquinone 26 (cLogD = 0.33) [8] exhibited low cytotoxicity,
comparable to that of the lead candidate 22 (cLogD = 0.41, Table 1). Furthermore, compound 26, when
tested on the NIH-3T3 cell line, was completely ineffective (IC50 > 100 µM) [8].
Molecules 2020, 25, 1530 5 of 8
Since it is known that a cLogD value > 1 is needed for drugs’ passive diffusion in mammalian
cells [21], then, the toxicity against HMEC-1 and NIH-3T3 cell lines showed by 22, 26, and 27 may be
related to their cLogD values (Table S1), in line with previously reported SARs [6,8,9].
Evaluation of the calculated selectivity indexes (SIs) for the two different mammalian cell lines (see
Table 1) of compounds 26 and 27 allowed a more proper assessment of their potential as antiparasitic
agents. Even if their antiplasmodial and schistosomicidal potencies are comparable, compound 26 can
be considered a better agent active against multiple parasites than 27 on the basis of its higher SI ratio
on HMEC cells and its nontoxic effect on NIH-3T3 cells.
3. Materials and Methods
3.1. General Experimental Procedures
Commercial reagents and solvents: Sigma-Aldrich (Saint Louis, MO, USA) and Carlo Erba
(Pomezia, Rome, Italy) whereas the anhydrous solvents were provided by Sigma-Aldrich or prepared
by distillation according to standard procedures. Qualitative and semiquantitative TLC analyses: silica
Gel 60 F254 (plates 5 × 20, 0.25 mm) and silica Gel 60 F254 plates (20 × 20.2 mm), respectively, Merck
(Kenilworth, NJ, USA). Spots were revealed by a UV lamp, and then by spraying with 2 N sulfuric acid
and heating at 120 ◦C. High-resolution electrospray ionization-mass spectrometry (ESI-MS (positive
mode)) was performed on a Thermo LTQ Orbitrap XL mass spectrometer (Thermo-Fisher, San Josè,
CA, USA) recording the spectra by infusion into the ESI source using MeOH as solvent.
NMR analysis was performed by a Bruker Avance Neo (Billerica, MA, USA) 700 MHz (700 and
175 MHz for 1H and 13C NMR, respectively). Chemical shifts were referenced to the residual solvent
signal (CDCl3: δH = 7.26 and δC = 77.0). Homonuclear 1H connectivity was determined by correlation
spectroscopy (COSY) experiments; one-bond heteronuclear 1H-13C connectivity by the heteronuclear
single quantum coherence (HSQC) experiment; and two- and three-bond 1H-13C connectivity by
gradient-HMBC experiments optimized for a 2,3J value of 8 Hz [22,23]. High-performance liquid
chromatography (HPLC) separations were performed both on a Shimadzu LC-10AT (Shimadzu, Milan,
Italy) apparatus and on a Knauer K-501 apparatus (LabService Analytica s.r.l., Anzola dell’Emilia,
Italy). Each instrument was equipped with a Knauer K-2301 RI detector.
3.2. Synthesis of the Compounds 24–27
The synthetic procedure needed to obtain the several thiazinoquinones 24–27 was already reported
in our previous work. In particular, the protocol provided a good outcome for our interested compounds,
confirming its interesting adaptability to different substrates [14].
Compound 24: orange powder; tR = 14 min (single peak). 1H NMR in CDCl3 and HRESIMS spectra
are reported in Supporting Information (SI). HRESIMS: m/z [M + Na]+ calcd. for C16H14ClNO5SNa+:
390.0173, found: 390.0171.
Compound 25: orange powder; tR = 21 min (single peak). 1H NMR in CDCl3 and HRESIMS spectra
are reported in Supporting Information (SI). HRESIMS: m/z [M + Na]+ calcd. for C17H14F3NO5SNa+:
424.0437, found: 424.0438.
Compound 26: dark orange powder; tR = 22 min (single peak). 1H NMR in CDCl3 and HRESIMS
spectra are reported in Supporting Information (SI). HRESIMS: m/z [M + H]+ calcd. for C17H18NO6S+:
364.0849, found: 364.0845.
Compound 27: orange powder; tR = 14 min (single peak). 1H NMR in CDCl3 and HRESIMS spectra
are reported in Supporting Information (SI). HRESIMS: m/z [M + H]+ calcd. for C17H15F3NO6S+:
418.0555, found: 418.0556.
3.3. P. falciparum Cultures and Drug Susceptibility Assay
All reagents were from Sigma Aldrich, Milan, Italy unless indicated otherwise. As reported in the
literature [20], the chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum
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were maintained in vitro at 5% hematocrit medium (constituted of human type Apositive red blood
cells) in RPMI 1640 (EuroClone, Celbio, Italy) with the addition of 1% AlbuMax (Invitrogen, Milan,
Italy), 0.01% hypoxanthine, 20 µM HEPES, and 2 µM glutamine. The resulting cultures were incubated
at 37 ◦C in a mixture of standard gas with the following composition: 1% O2, 5% CO2, and 94% N2.
Drug susceptibility assay was required to solubilize the tested compounds in DMSO, and subsequently,
diluted with the medium until the required concentration in order to have a final DMSO concentration
less than 1% that was not toxic for the parasites. Drugs were placed in 96 well flat-bottom microplates
and a series of dilutions performed. Asynchronous cultures (parasitemia of 1–1.5%; 1% final hematocrit)
were aliquoted into the plates and incubated for 72 h at 37 ◦C. The cultures were washed with PBS
before the chemosensitivity assay while the parasite growth was determined spectrophotometrically
(OD650) by measuring the parasite lactate dehydrogenase (pLDH) activity. These measurements
were made according to the modified version of Makler’s method both in control and drug-tested
cultures [20]. Antiplasmodial activity is expressed as 50% inhibitory concentrations (IC50), which
means the dose of compounds necessary to inhibit cell growth by 50%. Each IC50 value is the mean
standard deviation of at least three separate experiments performed in duplicate.
3.4. Cytotoxicity Assay
The HMEC-1 cell line immortalized by SV 40 large T antigen43 was maintained in MCDB 131
medium (Invitrogen, Milan, Italy) supplemented with 10% heat-inactivated fetal calf serum (HyClone,
Celbio, Milan, Italy), 10 ng/mL of epidermal growth factor (Chemicon), 1 mg/mL of hydrocortisone,
2 µM glutamine, 100 U/mL of penicillin, 100 mg/mL of streptomycin, and 20 µM of Hepes buffer
(EuroClone).
4. Conclusions
In this communication, our aim was to investigate the effects against P. falciparum strains and
HMEC-1 cell line of a series of methoxy p-benzyl-substituted thiazinoquinones (24–27) designed from
compound 22, earlier pointed out as an antimalarial lead candidate. For compounds 24–27, each
modification on the benzyl ring linked to the quinone moiety did not enhance the antiplasmodial
activity, which was decreased with respect to compound 22 but, in any case, preserved. In the series,
it is worthy to note that the more compelling compounds were 26 and 27, which showed IC50 values
against P. falciparum in the micromolar and sub-micromolar range. In summary, the results obtained
expanded our SAR studies on substituted thiazinoquinones as antiparasitic agents, indicating that
antiplasmodial activity is not affected by the inductive effect but rather by the (electron donating)
resonance effect of the introduced substituent at the para position of the benzyl ring. The achieved data
are an integral part of our ongoing investigation to identify new suitable antiparasitic agents whose
therapeutic potential could be exploited in co-infection processes caused by more than one human
parasite. Indeed, the current survey was based on the evaluation of antiparasitic usefulness as well as
the selectivity on mammalian cells of the thiazinoquinones 24–27, hence upgrading the knowledge
about the active thiazinoquinone scaffold.
Considering the overall obtained antiplasmodial effects, the reported properties against all stages
of the blood-dwelling S. mansoni [8], and the interference on the mammalian cells’ viability (HMEC-1
and NIH-3T3), we might define compound 26 as a new promising dual-acting antiparasitic agent
since it showed itself as being superior among antiparasitic and antiproliferative effects. Finally, these
studies corroborated the interesting potential of the bicyclic 1,1-dioxo-1,4-thiazine moiety as an active
chemotype effective on more than one neglected parasite and, hence, able to vanquish the serious
problem of the co-infection that is currently the cause of a high morbidity percentage in the most
vulnerable countries worldwide.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/7/1530/s1,
Figure S1: HRESIMS spectrum of compound 24, Figure S2: 1H NMR spectrum of compound 24 in CDCl3,
Figure S3: HRESIMS spectrum of compound 25, Figure S4: 1H NMR spectrum of compound 25 in CDCl3,
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Figure S5: HRESIMS spectrum of compound 26, Figure S6: 1H NMR spectrum of compound 26 in CDCl3,
Figure S7: HRESIMS spectrum of compound 27, Figure S8: 1H NMR spectrum of compound 27 in CDCl3, Table S1:
cLogD values of compounds 22 and 24–27.
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